References

What is myasthenia gravis

10.1001/jama.2023.16872 · 2024 · External reference

Myasthenia gravis. Update on diagnosis and therapy

10.1016/j.medcli.2023.04.006 · 2023 · External reference

Thymectomy and risk of generalization in patients with ocular myasthenia gravis: A multicenter retrospective cohort study

10.1007/s13311-021-01129-z · 2021 · External reference

Ocular myasthenia gravis: a review and practical guide for clinicians

10.1080/08164622.2022.2029683 · 2022 · External reference

Ocular myasthenia gravis: updates on an elusive target

10.1097/wco.0000000000000775 · 2020 · External reference

Pediatric ocular myasthenia gravis: Single-center experience

10.1016/j.pediatrneurol.2024.01.014 · 2024 · External reference

Risk factors for generalization in patients with ocular myasthenia gravis: A multicenter retrospective cohort study

10.1007/s40120-021-00292-x · 2022 · External reference

Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a propensity score analysis

10.1111/ene.15292 · 2022 · External reference

Immunotherapy for ocular myasthenia gravis: an observational study in Japan

10.1177/17562864231163819 · 2023 · External reference

Efgartigimod: a review in generalised myasthenia gravis

10.1007/s40265-024-02101-9 · 2024 · External reference

Eculizumab: a review in generalized myasthenia gravis

10.1007/s40265-018-0875-9 · 2018 · External reference

B cells in the pathophysiology of myasthenia gravis

10.1002/mus.25973 · 2018 · External reference

B cell-directed therapy in autoimmunity

10.1146/annurev-immunol-083122-044829 · 2024 · External reference

Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study

10.1111/ene.14391 · 2020 · External reference

Anti-CD19 CAR T cells for refractory myasthenia gravis

10.1016/s1474-4422(23)00375-7 · 2023 · External reference

Telitacicept: first approval

10.1007/s40265-021-01591-1 · 2021 · External reference

A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis

10.1111/ene.16322 · 2024 · External reference

Add-on telitacicept significantly improves outcome of patients with refractory ocular myasthenia gravis a real-world case series

10.1002/brb3.71157 · 2026 · External reference

AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis

10.1212/nxi.0000000000200436 · 2025 · External reference

Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology

10.1073/pnas.2505984122 · 2025 · External reference

C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis

10.1136/jnnp-2024-334404 · 2025 · External reference

Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis

10.1212/nxi.0000000000001169 · 2022 · External reference

Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis

10.1056/nejm198209233071301 · 1982 · External reference

Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis

10.1007/s00415-022-11048-4 · 2022 · External reference

High kappa free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis

10.1212/nxi.0000000000000831 · 2020 · External reference

A phase 3 trial of telitacicept for systemic lupus erythematosus

10.1056/nejmoa2414719 · 2025 · External reference

Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial

10.1093/rheumatology/kead265 · 2024 · External reference

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

10.1136/ard-2023-224854 · 2024 · External reference